EMA/602320/2022

# European Medicines Agency decision

P/0237/2022

of 8 July 2022

on the acceptance of a modification of an agreed paediatric investigation plan for ixazomib (Ninlaro), (EMEA-001410-PIP02-17-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Disclaimer**

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**

# European Medicines Agency decision

P/0237/2022

of 8 July 2022

on the acceptance of a modification of an agreed paediatric investigation plan for ixazomib (Ninlaro), (EMEA-001410-PIP02-17-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0125/2018 issued on 11 April 2018, decision P/0376/2018 issued on 7 December 2018, decision P/0261/2019 issued on 16 July 2019, and decision P/0351/2020 issued on 9 September 2020,

Having regard to the application submitted by Takeda Pharma A/S on 21 February 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 20 May 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

***Article 1***

Changes to the agreed paediatric investigation plan for ixazomib (Ninlaro), capsule, hard, powder for solution for injection, oral use, gastric use, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

***Article 2***

This decision is addressed to Takeda Pharma A/S, Delta Park 45, 2665 - Vallensbaek Strand, Denmark.

EMA/PDCO/117510/2022
Amsterdam, 20 May 2022

# Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001410-PIP02-17-M04

## Scope of the application

**Active substance(s):**

Ixazomib

**Invented name:**

Ninlaro

**Condition(s):**

Treatment of lymphoid malignancies (excluding multiple myeloma)

Treatment of multiple myeloma

**Authorised indication(s):**

See Annex II

**Pharmaceutical form(s):**

Capsule, hard

Powder for solution for injection

**Route(s) of administration:**

Oral use

Gastric use

Intravenous use

**Name/corporate name of the PIP applicant:**

Takeda Pharma A/S

**Information about the authorised medicinal product:**

See Annex II

## Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Takeda Pharma A/S submitted to the European Medicines Agency on 21 February 2022 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0125/2018 issued on 11 April 2018, decision P/0376/2018 issued on 7 December 2018, decision P/0261/2019 issued on 16 July 2019, and decision P/0351/2020 issued on 9 September 2020.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 21 March 2022.

## Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

## Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

# Annex I

# The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

# 1. Waiver

## *1.1. Condition*

Treatment of multiple myeloma

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- powder for solution for injection, capsule, hard, intravenous use, oral use, gastric use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subsets.

# 2. Paediatric investigation plan

## *2.1. Condition*

Treatment of lymphoid malignancies (excluding multiple myeloma)

### 2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients from birth to less than 18 years of age with a lymphoid malignancy

### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

### 2.1.3. Pharmaceutical form(s)

Powder for solution for injection

Capsule, hard

### 2.1.4. Measures

| Area | Description |
|---|---|
| Quality-related studies | **Study 1**<br>Compatibility of ixazomib powder for solution for injection, oral use, gastric use, with flavouring agents or food and with naso-gastric feeding tubes. Generation of data on acceptability and palatability |
| Non-clinical studies | Not applicable |

| | |
|---|---|
| Clinical studies | **Study 2 (T2017-002)**<br><br>Uncontrolled, open label study to assess pharmacokinetics and safety of ixazomib capsules for oral use, and of powder for solution for injection, oral use and gastric use, in paediatric patients from birth to less than 18 years of age (and adults if diagnosed at less than 18 years of age) with relapsed/refractory acute lymphoblastic leukaemia or lymphoblastic lymphoma with or without extramedullary disease<br><br>**Study 3 - deleted as part of EMEA-001410-PIP02-17-M03**<br><br>**Study 4 (T2017-002)**<br><br>Open-label, single arm study to assess the efficacy of the addition of ixazomib, capsules for oral use, and powder for solution for injection, oral use and gastric use, to reinduction chemotherapy in paediatric patients from birth to less than 18 years of age (and adults if diagnosed at less than 18 years of age) with relapsed/refractory (RR) acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LLy) with or without extramedullary disease<br><br>**Study 5**<br><br>Randomised, controlled, open-label study to assess event free survival (EFS) of patients from birth to less than 18 years of age (and adults if diagnosed at less than 18 years of age) with relapsed or refractory (RR) acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LLy) with or without extramedullary disease treated with ixazomib in combination with vincristine, dexamethasone,<br>L-asparaginase, and doxorubicin (VXLD) chemotherapy versus VXLD chemotherapy alone<br><br>**Study 6**<br><br>Randomized, controlled study of modified augmented Berlin-Frankfurt-Münster (ABFM) regimen with bortezomib during induction/consolidation and intensification followed by maintenance therapy with/without ixazomib in patients from birth to less than 18 years of age (and adults if diagnosed at less than 18 years of age) with newly diagnosed ALL or LLy with or without extramedullary disease |
| Extrapolation, modelling and simulation studies | Not applicable |
| Other studies | Not applicable |
| Other measures | Not applicable |

# 3. Follow-up, completion and deferral of PIP

| | |
|---|---|
| Concerns on potential long term safety/efficacy issues in relation to paediatric use: | No |
| Date of completion of the paediatric investigation plan: | By December 2031 |
| Deferral for one or more measures contained in the paediatric investigation plan: | Yes |

# Annex II

# Information about the authorised medicinal product

## Condition(s) and authorised indication(s):

Treatment of multiple myeloma

Authorised indication:

- Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

## Authorised pharmaceutical form(s):

Hard capsule

## Authorised route(s) of administration:

Oral use